Sunday, 2 February 2020

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study - The Lancet

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study  The Lancet

from "phlebotomy" - Google News http://bit.ly/2OjLt2j

No comments:

Post a Comment